Browsing by Subject "Hemodialysis"
Now showing 1 - 5 of 5
Results Per Page
Sort Options
Item Cholecalciferol supplementation increases serum 25(OH)D3 levels in hemodialysis subjects with initial values in sub-optimal range(2008-12) Bollman, Lacey; Boylan, Mallory; Spallholz, Julian E.; Shen, Chwan-LiThe fact that vitamin D deficiency is common in the chronic kidney disease (CKD) population is widely known. The majority of hemodialysis (HD) subjects undergoing maintenance dialysis have been found to have vitamin D levels in the suboptimal range. Vitamin D deficiency is one of many abnormalities that predispose the HD patient to bone disease and increased risk of fractures. Methods: Subjects in the study were 87 HD subjects with a mean age of 59.4±13.6 years. Baseline and post vitamin D supplementation serum 25(OH)D3, bAP, intact parathyroid hormone (iPTH), and other bone related laboratory test results were obtained by chart review. In January 2008, 68 subjects with suboptimal serum vitamin D levels were provided with one bottle of over the counter (OTC) 1000 IU cholecalciferol capsules and were instructed to take one capsule per day and post- supplementation were taken after 20 weeks of treatment. Results: The mean ± standard deviation (SD) serum 25(OH)D3 baseline level of subjects was 16.0 ng/mL (normal range 16.0-74.0 ng/mL) and 44% of subjects had values < 16.0 ng/mL indicating suboptimal vitamin D status. The mean ± SD serum 25(OH)D3 level of complaint subjects who took over 40% of their vitamin D tablets (n=53) post treatment was 50.9 ± 14.8 ng/mL a value considered in normal range. The 25(OH)D3 mean concentration for non-compliant subjects (n=18) was 22.2 ng/mL from a baseline value of 15.9 ng/mL pre treatment. The serum bAP value was < 20 µg/L in 46.7% of subjects and > 50 µg/L (indicating high bone turnover) in 12.0% of subjects. Subjects with a mean bAP > 50 µg/L had significantly higher levels serum iPTH levels a stimulator of bone turnover, compared to the groups with normal and low bAP values (ANOVA, p<0.05) but group serum 25(OH)D3, calcium, and phosphorus means were not significantly different. Serum 25(OH)D3 levels were not significantly correlated to bAP (r = -0.036, p=0.741) or to iPTH (r =0.013, p=0.906). Conclusion: Our study demonstrates that daily supplementation of 1000 IU cholecalciferol for a period of 20 weeks can effectively increase vitamin D levels to normal range (>30 ng/mL) in hemodialysis subjects with vitamin D deficiency and/or vitamin D insufficiency. Serum 25(OH)D3 levels in HD subjects are not correlated to serum bAP or iPTH.Item Dietary compliance of hemodialysis patients: personality and demographic correlates(Texas Tech University, 1980-12) Alexander, Lelia HarrisonNot availableItem Mass transfer of dialyzable constituents during hemodialysis of uremic patients(Texas Tech University, 1975-08) Page, Gordon C.Not availableItem Taste acuity response to zinc supplementation in hemodialysis patients(Texas Tech University, 1980-05) Ryan-Crowe, Virginia CassNot availableItem The effects of chronic hemodialysis on verbal learning and memory(Texas Tech University, 1989-05) Gonzalez, Guillermo ErnestoThis study sought to determine whether significant changes occur in dialysands' ability to (a) immediately recall verbal information, (b) acquire verbal material to a criterion of one errorless trial, and (c) remember previously learned information after a 15-minute retention interval across the interdialytic cycle. Previous research indicates that memory functioning is mildly, to moderately impaired and fluctuates from one dialysis treatment to the next. However, no study reviewed to date was found to assess memory adequately. Investigators consistently failed to control for original learning. Instead, determinations about memory dysfunction have been made after presentation of information only once. An exploratory examination of organizational strategies also was undertaken in the present study. Since negative affective states are known to impact adversely on learning and memory performance, mood was also examined. Eighteen dialysis patients with various types of renal disease were administered alternate forms of a free recall learning test (FRLT) and the Profile of Mood Scale on two consecutive days: immediately prior to their midweek dialysis treatment (predialysis) and approximately 24 hours after their dialysis treatment (postdialysis). To minimize the effects of practice, treatment order was completely counterbalanced. Order of test administration, however, was incompletely counterbalanced. Serum chemistries (blood urea nitrogen and creatinine) were obtained after each testing session. Pre- to postdialysis performance differences in immediate memory, acquisition, retention, and subjective organization were not observed. Immediate memory span was within normal limits. All subjects learned the FRLTs to criterion and recalled an average of 87 percent of the previously learned material. Subjective organization had little effect on acquisition and recall of the FRLTs. Serum chemistries did not correlate with any of the performance measures. Despite significant daily changes in serum levels of toxic renal metabolites, there was no evidence to suggest that learning and memory functioning fluctuate across the interdialytic cycle. Significant intercorrelations between immediate memory and acquisition were observed. This finding cautions against making determinations about memory dysfunction in dialysis patients, especially if the material is presented only once and it exceeds their immediate memory span. Mood was not seen to play any role in dialysands' learning and memory performance.